Brazil Hemato Oncology Testing Market Size & Outlook

The hemato oncology testing market in Brazil is expected to reach a projected revenue of US$ 273.5 million by 2030. A compound annual growth rate of 12.2% is expected of Brazil hemato oncology testing market from 2025 to 2030.
Revenue, 2024 (US$M)
$138.4
Forecast, 2030 (US$M)
$273.5
CAGR, 2025 - 2030
12.2%
Report Coverage
Brazil

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Brazil hemato oncology testing market, 2018-2030 (US$M)

Brazil hemato oncology testing market, 2018-2030 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Brazil hemato oncology testing market highlights

  • The Brazil hemato oncology testing market generated a revenue of USD 138.4 million in 2024 and is expected to reach USD 273.5 million by 2030.
  • The Brazil market is expected to grow at a CAGR of 12.2% from 2025 to 2030.
  • In terms of segment, lymphoma was the largest revenue generating cancer type in 2024.
  • Lymphoma is the most lucrative cancer type segment registering the fastest growth during the forecast period.


Hemato oncology testing market data book summary

Market revenue in 2024USD 138.4 million
Market revenue in 2030USD 273.5 million
Growth rate12.2% (CAGR from 2025 to 2030)
Largest segmentLymphoma
Fastest growing segmentLymphoma
Historical data2018 - 2023
Base year2024
Forecast period2025 - 2030
Quantitative unitsRevenue in USD million
Market segmentationLeukemia, Lymphoma, MPNs, Other Cancers
Key market players worldwideRoche Holding AG, Abbott Laboratories, Qiagen NV, Danaher Corp, Thermo Fisher Scientific Inc, Bio-Rad Laboratories Inc, Illumina Inc, Bio-Techne Corp


Other key industry trends

  • In terms of revenue, Brazil accounted for 3.8% of the global hemato oncology testing market in 2024.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Latin America, Brazil hemato oncology testing market is projected to lead the regional market in terms of revenue in 2030.
  • Argentina is the fastest growing regional market in Latin America and is projected to reach USD 82.1 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Hemato Oncology Testing Market Companies

Name Profile # Employees HQ Website
Bio-Techne Corp View profile 3050 614 McKinley Place N.E., Minneapolis, MN, United States, 55413 https://www.bio-techne.com
Qiagen NV View profile 5900 Hulsterweg 82, Venlo, LI, Netherlands, 5912 PL https://www.qiagen.com
Bio-Rad Laboratories Inc View profile 8030 1000 Alfred Nobel Drive, Hercules, CA, United States, 94547 https://www.bio-rad.com
Illumina Inc View profile 9300 5200 Illumina Way, San Diego, CA, United States, 92122 https://www.illumina.com
Danaher Corp View profile 63000 2200 Pennsylvania Avenue, N.W., Suite 800W, Washington, DC, United States, 20037-1701 https://www.danaher.com
Roche Holding AG View profile 103605 Grenzacherstrasse 124, Basel, Switzerland, 4070 https://www.roche.com
Thermo Fisher Scientific Inc View profile 122000 168 Third Avenue, Waltham, MA, United States, 02451 https://www.thermofisher.com
Abbott Laboratories View profile 114000 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400 https://www.abbottinvestor.com

Brazil hemato oncology testing market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hemato oncology testing market will help companies and investors design strategic landscapes.


Lymphoma was the largest segment with a revenue share of 52.02% in 2024. Horizon Databook has segmented the Brazil hemato oncology testing market based on leukemia, lymphoma, mpns, other cancers covering the revenue growth of each sub-segment from 2018 to 2030.


Brazil is expected to account for the largest share in the Latin America market and is anticipated to maintain its dominance over the forecast period. The large market can be attributed to increased access to testing kits in the market, high awareness as compared with other Latin American countries, and local presence of major market players.

Furthermore, increasing initiatives by several organizations such as the Brazilian Association of Lymphoma and Leukemia (ABRALE) to increase awareness about early diagnosis and treatment of diseases is expected to support the market growth.

In addition to this, increasing prevalence of hemato oncology cases will further drive the market growth in the review period. According to data published by Globocan 2020, around 11,396 new cases of leukemia, 11,445 new cases of non-Hodgkin lymphoma, and 3,254 new cases of Hodgkin lymphoma were estimated to be diagnosed in the country.

Reasons to subscribe to Brazil hemato oncology testing market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Brazil hemato oncology testing market databook

  • Our clientele includes a mix of hemato oncology testing market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the Brazil hemato oncology testing market , including forecasts for subscribers. This country databook contains high-level insights into Brazil hemato oncology testing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Brazil hemato oncology testing market size, by cancer type, 2018-2030 (US$M)

Brazil Hemato Oncology Testing Market Outlook Share, 2024 & 2030 (US$M)

Brazil hemato oncology testing market size, by cancer type, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online